Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Future trials should enrich truly deficient, higher-risk phenotypes, standardize regimens, and prioritize event-driven hard endpoints with embedded mechanistic markers to confirm on-target biology
Greater insulin release with exendin-phe1 was unlikely to result from cross-reactivity with other incretin receptors, as it was blocked with the GLP-1R orthosteric antagonist exendin(9-39) (Supplementary Fig
On safety, the picture is reassuring within the studied context
Suggestive associations also existed between total bilirubin and RC risk (OR = 0.97
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
